ReviewDrug design, development and therapy2026
Hypericin as a Photodynamic Immunomodulator: A Natural Compound for Dermatological Therapy.
Review in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Method for Isolating Hypericin fromMolecules (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypericin, a polycyclic quinone derived from *Hypericum perforatum* (St. John's Wort), has gained attention for its broad pharmacological activities, including anti-inflammatory, antimicrobial, and antitumor effects. It modulates key signaling pathways like NF-κB and MAPK, reducing chronic inflammation and making it effective in treating autoimmune and infectious skin conditions. As a photosensitizer, hypericin also induces apoptosis in abnormal cells through photodynamic therapy (PDT), showing promising results in treating cutaneous T-cell lymphoma (CTCL), psoriasis, and fungal infections. While its solubility and bioavailability remain challenges, hypericin's favorable safety profile and therapeutic potential position it as a valuable option for managing refractory dermatological conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.